Neoadjuvant Combination Immunotherapy for Stage III Melanoma
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Determine safety and efficacy of pre-operative combination immunotherapy with Talimogene
Laherparepvec (T-VEC)/Pembrolizumab given prior to complete lymph node dissection in
resectable stage 3 cutaneous melanoma with clinically apparent lymph node metastases.